Author:
,K. Konidala Sathish,Kotra Vijay,Samineni Ramu,R. Shaik Abdul,S. Nissankara Rao Lakshmi,N. Jamullamudi Risy,K. Kola Phani
Abstract
The present work aimed to explore efficient lead molecules to combat against COVID-19. Despite the extensive usage of repurposed medications for COVID-19 therapy due to their inadequacy to proper control of endangered pandemic, there is an urgent need to discover innovative compounds that are very effective against the COVID-19 pandemic. Newly synthesized coumarin-chalcone hybrids were assessed for their efficacy to inhibit main protease 6LU7(Mpro) and compared it with some repurposing COVID-19 drug activity through in silico technique. Among all synthesized hybrids, d11, a11, c12, b11 and c5, showed highest binding affinities with the least docking score against protease (PDB ID: 6LU7) protein comparable to repurposed drugs currently used against COVID-19. The selected hybrids having coumarin, chalcone, and dihydropyridine pharmacophores are promising for their anti-COVID-19 activity. However, further extensive research is required through suitable in vitro and in vivo methods.
Publisher
Indian Drug Manufacturers' Association (IDMA)
Reference32 articles.
1. 1. Cascella M., Rajnik M., Cuomo A., Dulebohn S.C., Di N.R.: Features, evaluation and treatment coronavirus (COVID-19). In:Statpearls [internet], Treasure Island (FL), 2021.
2. 2. Kickbusch I., Leung G.: Response to the emerging novel coronavirus outbreak. BMJ 2020, 368 m406.
3. 3. World health organization, Coronavirus disease (COVID-19) pandemic https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed date: 06 July 2023.
4. 4. Wang L.S., Wang Y.R., Ye D.W., Liu Q.Q.: A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int. J. Antimicrob. Agents., 2020, 105948.
5. 5. Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y.: The epidemiology, diagnosis, and treatment of COVID-19. Int. J. Antimicrob. Agents., 2020, 105955.